MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.78 (117.64% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016MizuhoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Noble FinancialInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Piper JaffrayReiterated RatingOverweight$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q1($0.76)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.81)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.72)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q414($0.74)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015$0.64$0.50ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.44)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.81$0.88$18.75 million$25.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.88)($0.88)($0.88)
Q4 20161($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)
Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline
06/25/16 02:19 PMStock Grabbing Investor's Attention: Adamas Pharmaceuticals, Inc. (ADMS) - iStreetWire
06/24/16 02:19 PMStrong Sell Calls Recommendations For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire
06/24/16 10:27 AMTaking A Look At Adamas Pharmaceuticals Inc (ADMS)'s Upcoming Parkinson's NDA - Insider Monkey (blog)
06/23/16 12:10 PMTaking A Look At Adamas Pharmaceuticals Inc (ADMS)’s Upcoming Parkinson’s NDA -
06/23/16 10:03 AMAdamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted
06/22/16 07:30 PMAdamas Pharmaceuticals Inc. (ADMS) Drops 7.97% on June 21 - Equities.com
06/22/16 02:19 PMAdamas Pharmaceuticals (ADMS) Weak On High Volume Today - TheStreet.com
06/22/16 07:05 AMAdamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted - StreetInsider.com
06/22/16 05:09 AMAdamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders - [at noodls] - EMERYVILLE, Calif., June 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release ...
06/22/16 05:01 AM6:01 am Adamas Pharmaceuticals announces additional data from its Phase 3 clinical program of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease at the International Congr -
06/22/16 05:00 AMAdamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - EMERYVILLE, Calif., June 22, 2016-- Adamas Pharmaceuticals, Inc. today announced additional data from its Phase 3 clinical program of ADS-5102 extended-release capsules for the treatment of levodopa-induced ...
06/21/16 02:16 PMAdamas Pharmaceuticals, Inc. (ADMS) Current Analyst Ratings - Fiscal Standard
06/20/16 08:50 AMAnalyst Views For The Week Ahead: Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard
06/18/16 02:18 PMStrong Buy Calls Count For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 6 - Investor Newswire
06/17/16 02:18 PMStrong Buy Calls Count For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 5 - Investor Newswire
06/14/16 07:05 AMRVNC Wrinkled, MRNS Jolted As Study Fails, BSTC Abuzz, FDA Snubs KMPH
06/13/16 02:18 PMAdamas Pharma (ADMS) Announces Positive Data from ADS-5102 Phase 2 POC as MS-Related Treatment - StreetInsider.com
06/13/16 10:26 AMData Supports Further Clinical Development of ADS-5102 in MS
06/13/16 07:19 AMAdamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients - [at noodls] - EMERYVILLE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 ...
06/13/16 07:13 AMAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : June 13, 2016 -
06/06/16 11:12 AMADAMAS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/05/16 02:19 PMAdamas Pharmaceuticals, Inc. (ADMS) Broker Price Targets For The Coming Week - Share Trading News
06/03/16 08:20 PMGreat Point Partners LLC Increased Adamas Pharmaceuticals INC (NASDAQ:ADMS) by $9.40 Million as Shares ... - CCH Daily News
06/03/16 10:46 AMAdamas Pharmaceuticals, Inc. (ADMS) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/01/16 02:19 PMStrong Sell Calls Count For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire - Strong Sell Calls Count For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0Investor NewswireAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has a total of 5 Strong Buy calls and 0 Strong Sell advises as of 2016-05-31. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
06/01/16 10:41 AMBuy, Sell Or Hold Rating For Adamas Pharmaceuticals, Inc. (ADMS)? - Share Trading News - Buy, Sell Or Hold Rating For Adamas Pharmaceuticals, Inc. (ADMS)?Share Trading News01/19/2016 – Cowen began new coverage on Adamas Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 45 price target on the stock. 01/12/2016 – Adamas Pharmaceuticals, Inc. had its “overweight” rating reiterated by ...Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Shorted Shares Increased By 20.44%HNNall 2 news articles »
05/24/16 01:41 PMETF’s with exposure to Adamas Pharmaceuticals, Inc. : May 24, 2016 -
05/23/16 07:08 AMAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : May 23, 2016 -
05/20/16 08:35 AMAdamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 05:12 PMAdamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders - [at noodls] - EMERYVILLE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company's Phase 3 clinical program ...
05/16/16 05:00 PMAdamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson’s and Movement Disorders - [GlobeNewswire] - EMERYVILLE, Calif., May 16, 2016-- Adamas Pharmaceuticals, Inc. today announced that data from EASE LID and EASE LID 2, trials from the company’ s Phase 3 clinical program of ADS-5102 for the treatment ...
05/10/16 05:01 PMAdamas reports 1Q loss -
05/10/16 03:28 PMAdamas Reports First Quarter 2016 Financial Results - [at noodls] - EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016. Adamas ended the quarter with $169.2 million ...
05/10/16 03:07 PMADAMAS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/06/16 04:54 PMAdamas Announces New Employment Inducement Grant - [at noodls] - EMERYVILLE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received a ...
05/06/16 07:34 AMAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : May 6, 2016 -
02/27/16 12:04 PMADAMAS PHARMACEUTICALS INC Financials -
02/26/16 10:59 AMUpdated Price Targets On Adamas Pharmaceuticals, Inc. (ADMS) - Risers & Fallers - Updated Price Targets On Adamas Pharmaceuticals, Inc. (ADMS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Adamas Pharmaceuticals, Inc. (ADMS). The latest broker reports which are currently outstanding on Friday 26th of February state 1 analyst has a rating of “strong buy”, ...Adamas Pharmaceuticals' (ADMS) Neutral Rating Reaffirmed at MizuhoThe Vista VoiceStocks Favored by Analysts: Solaredge Technologies Inc (NASDAQ:SEDG), First Busey Corporation (NASDAQ:BUSE ...RiversideGazette.comall 3 news articles »
02/26/16 10:59 AMIs the Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Pullback an Opportunity? - On February 24, 2016, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) opened the session at a little over $14 a share. By session close, it traded for $12.80 – a 13.5% decline in one day. The decline came off the back of the company’s fourth quarter and ...
02/25/16 09:26 AMAdamas Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers -
02/23/16 03:21 PMADAMAS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
02/23/16 03:05 PMAdamas Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - EMERYVILLE, Calif., Feb. 23, 2016-- Adamas Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2015. Adamas reported a net loss attributable ...
02/22/16 03:05 PMAdamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences - [GlobeNewswire] - EMERYVILLE, Calif., Feb. 22, 2016-- Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at two upcoming healthcare conferences--. ...
02/14/16 12:50 PMAdamas Pharmaceuticals Inc (ADMS) Jumps 5.47% on February 12 - Equities.com - Adamas Pharmaceuticals Inc (ADMS) Jumps 5.47% on February 12Equities.comAdamas Pharmaceuticals Inc (ADMS) was among the biggest gainers on the Russell 2000 for Friday February 12 as the stock popped 5.47% to $14.26, representing a gain of $0.74 per share. Some 144,131 shares traded hands on 1,197 trades, compared ...Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Sellers Increased By 14% Their Shortsfdanewsalert.comall 55 news articles »
02/11/16 02:01 PMPrice Target Update On Adamas Pharmaceuticals, Inc. (ADMS) - Risers & Fallers - Price Target Update On Adamas Pharmaceuticals, Inc. (ADMS)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Adamas Pharmaceuticals, Inc. (ADMS). According to the latest broker reports 1 analyst has a rating of “buy”, 5 analysts “outperform”, 1 analysts “hold”, 0 analysts ...and more »
02/09/16 01:25 PMAdamas Pharmaceuticals Inc (NASDAQ:ADMS) Receives Average Rating of “Buy” from Brokerages - Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been assigned an average recommendation of “Buy” from the nine brokerages that are currently covering the company, Market Beat Ratings reports. Three analysts have rated the stock with a hold recommendation ...
02/07/16 12:36 PMAdamas Pharmaceuticals Inc (ADMS) Drops 5.13% on February 05 - Equities.com - Adamas Pharmaceuticals Inc (ADMS) Drops 5.13% on February 05Equities.comAdamas Pharmaceuticals Inc (ADMS) was one of the Russell 2000's biggest losers for Friday February 05 as the stock slid 5.13% to $15.55, a loss of $-0.84 per share. Starting at an opening price of $16.25 a share, the stock traded between $15.46 and ...and more »
02/05/16 01:03 PMAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Shorted Shares Decreased By 18.75% - fdanewsalert.com - Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Shorted Shares Decreased By 18.75%fdanewsalert.comAdamas Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems . The company has a market cap of $342.82 million. It is engaged in ...and more »
01/29/16 12:27 PMAnalyst Price Target on Adamas Pharmaceuticals, Inc. - Market Briefing - Analyst Price Target on Adamas Pharmaceuticals, Inc.Market BriefingAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) stock has received a short term price target of $ 43.67 from 3 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $1.53.and more »
01/28/16 07:15 PMAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS): Quarterly Earnings Update - Investor Newswire - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS): Quarterly Earnings UpdateInvestor NewswireAs per the brokerage research firms surveyed by Zacks Research, Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is expected to post earnings per share of $-0.57 for last fiscal quarter. The company can announce the results on or around 2016-03-01.and more »
About Adamas Pharmaceuticals

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Its ADS-5102 is an extended-release version of amantadine that is intended for once daily administration at bedtime. It is developing ADS-8704, which is a fixed-dose combination of its controlled release version of memantine and donepezil for the treatment of moderate to severe dementia related to Alzheimer's disease. Its ADS 8902, a triple combination antiviral drug therapy for influenza. It also offers Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules (formerly MDX-8704) and Namenda XR (memantine hydrochloride) extended release capsules.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMS
  • CUSIP:
Key Metrics:
  • Previous Close: $16.24
  • 50 Day Moving Average: $16.15
  • 200 Day Moving Average: $17.16
  • P/E Ratio: N/A
  • P/E Growth: -0.06
  • Market Cap: $335.65M
  • Current Quarter EPS Consensus Estimate: $-3.09 EPS
Additional Links:
Adamas Pharmaceuticals (NASDAQ:ADMS) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha